← Back to Search

Anti-metabolites

Tumor Cell Vaccine + Cytoxan for Neuroblastoma (ATOMIC Trial)

Phase 1 & 2
Waitlist Available
Led By Andras A. Heczey, MD
Research Sponsored by Baylor College of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically proven high risk neuroblastoma in first or subsequent relapse or with primary refractory disease or inability to complete standard therapy
Age less than 21 at time of initial diagnosis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 15 years
Awards & highlights

ATOMIC Trial Summary

This trial is testing an experimental treatment for neuroblastoma, which is a solid tumor that is the second most common cancer in children. The treatment consists of a series of immunizations using a tumor vaccine, combined with low-dose chemotherapy taken by mouth on a daily basis. The hope is that the vaccine will cause the immune system to recognize and kill more types of neuroblastoma tumors. Additionally, the immunizations will be combined with daily low dose chemotherapy.

Who is the study for?
This trial is for children under 21 with high-risk neuroblastoma that's relapsed or didn't respond to treatment. They must have a certain level of physical function, blood counts, liver and kidney function, not be pregnant or breastfeeding, and able to follow the study plan. Those who've had certain recent treatments or have severe infections, heart issues, HIV, or psychiatric conditions can't join.Check my eligibility
What is being tested?
The trial tests a new approach combining a neuroblastoma vaccine (with unmodified SKNLP cells and gene-modified SJNB-JF-IL2/SJNB-JF-LTN cells) with daily low-dose oral Cytoxan chemotherapy. The goal is to boost the immune system's ability to fight cancer by reducing tumor-protecting cells and attacking tumor blood vessels.See study design
What are the potential side effects?
Potential side effects include immune reactions from the vaccine leading to inflammation in various organs. Low-dose Cytoxan may cause nausea, hair loss, mouth sores, lowered immunity increasing infection risk; however specific side effects will be monitored throughout the trial.

ATOMIC Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My neuroblastoma is high risk and has either come back, didn't respond to treatment, or I couldn't complete standard therapy.
Select...
I was diagnosed before turning 21.
Select...
My kidney function is within the required range.
Select...
I am not pregnant and will use effective birth control during the study.
Select...
I am able to live with some level of independence.

ATOMIC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~15 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 15 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Secondary outcome measures
Number of Participants with Disease Progression as a Measure of Efficacy
Participants with T-cell changes as a Measure of Immune Response
Other outcome measures
Analysis of Immunologic Measurements

ATOMIC Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment PlanExperimental Treatment2 Interventions
Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells) and Cytoxan (Cyclophosphamide)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cytoxan
2007
Completed Phase 3
~1460

Find a Location

Who is running the clinical trial?

Center for Cell and Gene Therapy, Baylor College of MedicineOTHER
111 Previous Clinical Trials
2,806 Total Patients Enrolled
11 Trials studying Neuroblastoma
252 Patients Enrolled for Neuroblastoma
Baylor College of MedicineLead Sponsor
1,001 Previous Clinical Trials
6,002,169 Total Patients Enrolled
13 Trials studying Neuroblastoma
294 Patients Enrolled for Neuroblastoma
Andras A. Heczey, MDPrincipal InvestigatorBaylor College of Medicine
2 Previous Clinical Trials
18 Total Patients Enrolled
2 Trials studying Neuroblastoma
18 Patients Enrolled for Neuroblastoma

Media Library

Cytoxan (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT01192555 — Phase 1 & 2
Neuroblastoma Research Study Groups: Treatment Plan
Neuroblastoma Clinical Trial 2023: Cytoxan Highlights & Side Effects. Trial Name: NCT01192555 — Phase 1 & 2
Cytoxan (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01192555 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are currently involved in this trial?

"Unfortunately, this research has concluded its recruitment phase. The trial was initially announced on September 1st 2010 and the information was last updated on March 25th 2022. Fortunately, there are still many other medical trials including 161 studies related to Neuroblastoma and 816 involving a Neuroblastoma Vaccine (unmodified SKNLP with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells) that have ongoing patient enrollment."

Answered by AI

Is enrollment still available for this clinical experiment?

"Clinicaltrials.gov data suggests that this medical trial is not currently recruiting participants as of March 25, 2022; however, there are 977 other trials actively looking for patients at the present moment. The study was initially uploaded on September 1st 2010 and has been updated since then."

Answered by AI

What conditions are typically treated via the Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells)?

"Neuroblastoma Vaccine, which consists of unmodified SKNLP and gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells, is often prescribed to patients suffering from multiple sclerosis. In addition, this therapeutic approach can be employed in the management of mixed cell lymphomas, leukemias, myelocytic acutes, and retinoblastomas."

Answered by AI

Are there any records of similar research involving Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells?)

"Currently, 816 trials are running to explore the safety and efficacy of Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells). Of these studies, 154 have entered Phase 3. Philadelphia is a major hub for research on this treatment; however 27824 sites worldwide are conducting clinical trials related to it."

Answered by AI
~1 spots leftby Apr 2025